Last Updated: November 16, 2026

Expiring Drug Patents Cheat Sheet
We analyse the patents covering drugs in 134 countries and quickly give you the likely loss-of-exclusivity/generic entry date

➤ Get the Full List

Peru: These 14 Drugs Face Patent Expirations and Generic Entry From 2026 - 2027

The content of this page is licensed under a Creative Commons Attribution 4.0 International License. Creative Commons License

Preferred citation:
Friedman, Yali, "Peru: These 14 Drugs Face Patent Expirations and Generic Entry From 2026 - 2027" DrugPatentWatch.com thinkBiotech, 2026 www.drugpatentwatch.com/p/expiring-drug-patents-generic-entry/.
Media collateral
These estimated drug patent expiration dates and generic entry opportunity dates are calculated from analysis of known patents covering drugs. Many factors can influence early or late generic entry. This information is provided as a rough estimate of generic entry potential and should not be used as an independent source. The methodology is described in this blog post.
When can SIRTURO (bedaquiline fumarate) generic drug versions launch in Peru?

Generic name: bedaquiline fumarate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 05, 2026
Generic Entry Controlled by: Peru Patent 20,081,350
Patent Title: SAL FUMARATO DE (ALFAS S, BETA R)-6-BROMO-ALFA-[2(DIMETILAMINO)ETIL]-2-METOXI-ALFA-1-NAFTALENIL-BETA-FENIL-3-QUINOLINAETANOL

SIRTURO is a drug marketed by Janssen Therap. There are two patents protecting this drug.

See drug price trends for SIRTURO.

The generic ingredient in SIRTURO is bedaquiline fumarate. Additional details are available on the bedaquiline fumarate profile page.

When can ZYKADIA (ceritinib) generic drug versions launch in Peru?

Generic name: ceritinib
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 08, 2026
Generic Entry Controlled by: Peru Patent 20,081,447
Patent Title: COMPUESTOS Y COMPOSICIONES COMO INHIBIDORES DE LA PROTEINA CINASA

ZYKADIA is a drug marketed by Novartis. There are eight patents protecting this drug.

See drug price trends for ZYKADIA.

The generic ingredient in ZYKADIA is ceritinib. Additional details are available on the ceritinib profile page.

When can ZYKADIA (ceritinib) generic drug versions launch in Peru?

Generic name: ceritinib
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 08, 2026
Generic Entry Controlled by: Peru Patent 20,120,814
Patent Title: COMPUESTOS Y COMPOSICIONES COMO INHIBIDORES DE LA PROTEINA CINASA

ZYKADIA is a drug marketed by Novartis. There are eight patents protecting this drug.

See drug price trends for ZYKADIA.

The generic ingredient in ZYKADIA is ceritinib. Additional details are available on the ceritinib profile page.

When can NESINA (alogliptin benzoate) generic drug versions launch in Peru?

Generic name: alogliptin benzoate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: February 01, 2027
Generic Entry Controlled by: Peru Patent 20,081,734
Patent Title: COMPRIMIDO QUE COMPRENDE 2-[[6-[(3R)-3-AMINO-1-PIPERIDINIL]-3,4-DIHIDRO-3-METIL-2,4-DIOXO-1(2H)-PIRIMIDINIL]METIL]-BENZONITRILO Y CELULOSA MICROCRISTALINA

Drug Price Trends for NESINA
NESINA is a drug marketed by Takeda Pharms Usa. There are two patents protecting this drug and one Paragraph IV challenge. Two tentatively approved generics are ready to enter the market. There has been litigation on patents covering NESINA

See drug price trends for NESINA.

The generic ingredient in NESINA is alogliptin benzoate. Additional details are available on the alogliptin benzoate profile page.

When can OSENI (alogliptin benzoate; pioglitazone hydrochloride) generic drug versions launch in Peru?

Generic name: alogliptin benzoate; pioglitazone hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: February 01, 2027
Generic Entry Controlled by: Peru Patent 20,081,663

Drug Price Trends for OSENI
OSENI is a drug marketed by Takeda Pharms Usa. There are two patents protecting this drug. There has been litigation on patents covering OSENI

See drug price trends for OSENI.

The generic ingredient in OSENI is alogliptin benzoate; pioglitazone hydrochloride. Additional details are available on the alogliptin benzoate; pioglitazone hydrochloride profile page.

When can VARUBI (rolapitant hydrochloride) generic drug versions launch in Peru?

Generic name: rolapitant hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: March 22, 2027
Generic Entry Controlled by: Peru Patent 20,081,891
Patent Title: FORMULACIONES DE COMPRIMIDOS QUE CONTIENEN SALES DE 8-[{1-(3,5-BIS-(TRIFLUOROMETIL)FENIL)-ETOXI}-METIL]-8-FENIL-1,7-DIAZA-SPIRO[4.5]DECAN-2-ONA Y COMPRIMIDOS ELABORADOS A PARTIR DE ESTAS

VARUBI is a drug marketed by Tersera. There are eight patents protecting this drug.

The generic ingredient in VARUBI is rolapitant hydrochloride. Additional details are available on the rolapitant hydrochloride profile page.

When can EDARBI (azilsartan kamedoxomil) generic drug versions launch in Peru?

Generic name: azilsartan kamedoxomil
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: March 28, 2027
Generic Entry Controlled by: Peru Patent 20,090,550
Patent Title: COMPOSICION FARMACEUTICA SOLIDA QUE COMPRENDE UN DERIVADO DE BENCIMIDAZOL Y UN AGENTE DE CONTROL DE PH

Drug Price Trends for EDARBI
EDARBI is a drug marketed by Azurity. There is one patent protecting this drug. There has been litigation on patents covering EDARBI

See drug price trends for EDARBI.

The generic ingredient in EDARBI is azilsartan kamedoxomil. Additional details are available on the azilsartan kamedoxomil profile page.

When can PROMACTA (eltrombopag olamine) generic drug versions launch in Peru?

Generic name: eltrombopag olamine
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: May 03, 2027
Generic Entry Controlled by: Peru Patent 20,080,773

PROMACTA is a drug marketed by Novartis. There is one patent protecting this drug and two Paragraph IV challenges. There has been litigation on patents covering PROMACTA

See drug price trends for PROMACTA.

The generic ingredient in PROMACTA is eltrombopag olamine. Additional details are available on the eltrombopag olamine profile page.

When can PROMACTA (eltrombopag olamine) generic drug versions launch in Peru?

Generic name: eltrombopag olamine
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: May 03, 2027
Generic Entry Controlled by: Peru Patent 20,121,407
Patent Title: COMPOSICION FARMACEUTICA QUE COMPRENDE BIS-(MONOETANOLAMINA) DE ACIDO 3'-[(2Z)-[1-(3, 4-DIMETILFENIL)-1, 5-DIHIDRO-3-METIL-5-OXO-4H-PIRAZOL-4-ILIDENO] HIDRAZINO]-2'-HIDROXI-[1, 1'-BIFENIL]-3-CARBOXILICO

PROMACTA is a drug marketed by Novartis. There is one patent protecting this drug and two Paragraph IV challenges. There has been litigation on patents covering PROMACTA

See drug price trends for PROMACTA.

The generic ingredient in PROMACTA is eltrombopag olamine. Additional details are available on the eltrombopag olamine profile page.

When can SIGNIFOR LAR (pasireotide pamoate) generic drug versions launch in Peru?

Generic name: pasireotide pamoate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: May 24, 2027
Generic Entry Controlled by: Peru Patent 20,090,387
Patent Title: FORMULACION DE PASIREOTIDA

SIGNIFOR LAR is a drug marketed by Recordati Rare. There are three patents protecting this drug.

See drug price trends for SIGNIFOR LAR.

The generic ingredient in SIGNIFOR LAR is pasireotide pamoate. Additional details are available on the pasireotide pamoate profile page.

When can TEPMETKO (tepotinib hydrochloride) generic drug versions launch in Peru?

Generic name: tepotinib hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: July 12, 2027
Generic Entry Controlled by: Peru Patent 20,090,287
Patent Title: DERIVADOS DE PIRIDAZINONA

TEPMETKO is a drug marketed by Emd Serono Inc. There are eight patents protecting this drug. There has been litigation on patents covering TEPMETKO

See drug price trends for TEPMETKO.

The generic ingredient in TEPMETKO is tepotinib hydrochloride. Additional details are available on the tepotinib hydrochloride profile page.

When can KAZANO (alogliptin benzoate; metformin hydrochloride) generic drug versions launch in Peru?

Generic name: alogliptin benzoate; metformin hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: July 19, 2027
Generic Entry Controlled by: Peru Patent 20,090,882
Patent Title: PREPARACION SOLIDA QUE COMPRENDE ALOGLIPTINA Y CLORHIDRATO DE METFORMINA

Drug Price Trends for KAZANO
KAZANO is a drug marketed by Takeda Pharms Usa. There are two patents protecting this drug and one Paragraph IV challenge. There has been litigation on patents covering KAZANO

See drug price trends for KAZANO.

The generic ingredient in KAZANO is alogliptin benzoate; metformin hydrochloride. Additional details are available on the alogliptin benzoate; metformin hydrochloride profile page.

When can KAZANO (alogliptin benzoate; metformin hydrochloride) generic drug versions launch in Peru?

Generic name: alogliptin benzoate; metformin hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: July 19, 2027
Generic Entry Controlled by: Peru Patent 20,140,923
Patent Title: PREPARACION SOLIDA QUE COMPRENDE ALOGLIPTINA Y CLORHIDRATO DE METFORMINA

Drug Price Trends for KAZANO
KAZANO is a drug marketed by Takeda Pharms Usa. There are two patents protecting this drug and one Paragraph IV challenge. There has been litigation on patents covering KAZANO

See drug price trends for KAZANO.

The generic ingredient in KAZANO is alogliptin benzoate; metformin hydrochloride. Additional details are available on the alogliptin benzoate; metformin hydrochloride profile page.

When can PROMACTA (eltrombopag olamine) generic drug versions launch in Peru?

Generic name: eltrombopag olamine
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: July 31, 2027
Generic Entry Controlled by: Peru Patent 20,151,953
Patent Title: COMPOSICION FARMACEUTICA QUE COMPRENDE BIS-(MONOETANOLAMINA) DE ACIDO 3'-[(2Z)-[1-(3, 4-DIMETILFENIL)-1, 5-DIHIDRO-3-METIL-5-OXO-4H-PIRAZOL-4-ILIDENO] HIDRAZINO]-2'-HIDROXI-[1, 1'-BIFENIL]-3-CARBOXILICO

PROMACTA is a drug marketed by Novartis. There is one patent protecting this drug and two Paragraph IV challenges. There has been litigation on patents covering PROMACTA

See drug price trends for PROMACTA.

The generic ingredient in PROMACTA is eltrombopag olamine. Additional details are available on the eltrombopag olamine profile page.

When can DAKLINZA (daclatasvir dihydrochloride) generic drug versions launch in Peru?

Generic name: daclatasvir dihydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: August 09, 2027
Generic Entry Controlled by: Peru Patent 20,080,542
Patent Title: INHIBIDORES DEL VIRUS DE LA HEPATITIS C

Drug Price Trends for DAKLINZA
DAKLINZA is a drug marketed by Bristol-myers Squibb. There are five patents protecting this drug. There has been litigation on patents covering DAKLINZA

See drug price trends for DAKLINZA.

The generic ingredient in DAKLINZA is daclatasvir dihydrochloride. Additional details are available on the daclatasvir dihydrochloride profile page.

When can INTRAROSA (prasterone) generic drug versions launch in Peru?

Generic name: prasterone
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: August 10, 2027
Generic Entry Controlled by: Peru Patent 20,140,925
Patent Title: COMPOSICION FARMACEUTICA QUE COMPRENDE UN PRECURSOR DE ESTEROIDES SEXUALES

Drug Price Trends for INTRAROSA
INTRAROSA is a drug marketed by Millicent. There are three patents protecting this drug. There has been litigation on patents covering INTRAROSA

See drug price trends for INTRAROSA.

The generic ingredient in INTRAROSA is prasterone. Additional details are available on the prasterone profile page.

When can ALIQOPA (copanlisib dihydrochloride) generic drug versions launch in Peru?

Generic name: copanlisib dihydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 04, 2027
Generic Entry Controlled by: Peru Patent 20,081,444
Patent Title: DERIVADOS DE 2,3-DIHIDROIMIDAZO[1,2-C]QUINAZOLINA SUSTITUIDA UTILES PARA EL TRATAMIENTO DE ENFERMEDADES Y TRASTORNOS HIPER-PROLIFERATIVOS ASOCIADOS CON LA ANGIOGENESIS

ALIQOPA is a drug marketed by Bayer Healthcare. There are three patents protecting this drug.

See drug price trends for ALIQOPA.

The generic ingredient in ALIQOPA is copanlisib dihydrochloride. Additional details are available on the copanlisib dihydrochloride profile page.

Peru Branded and Generic Drug Market Assessment: Regulation, Market Access, Patents, and Commercial Opportunities

Last updated: October 14, 2026

Peru’s pharmaceutical market is divided between a fragmented private retail channel and a procurement-driven public sector. Branded products retain strong physician and consumer recognition, while generics by international nonproprietary name (INN) compete mainly on price and public tenders. The principal opportunities are generic substitution, hospital medicines, biosimilars, specialty therapies, local manufacturing, and regulatory consulting. The main constraints are uneven enforcement, lengthy registration and variation procedures, centralized purchasing, price sensitivity, weak interchangeability adoption, and limited regulatory predictability.

DIGEMID, the General Directorate of Medicines, Supplies and Drugs, regulates registration, pharmacovigilance, quality, distribution, and market surveillance. INDECOPI administers industrial property rights, including pharmaceutical patents. MINSA, through CENARES and other purchasing entities, is the largest institutional buyer.

What is the structure of Peru’s branded and generic drug market?

Peru has three commercially distinct pharmaceutical segments:

Segment Main products Primary buyers Commercial characteristics
Innovative brands Originator drugs protected by patents, data rights, or brand equity Private patients, specialists, private clinics, public tenders High price, specialist promotion, hospital and specialty focus
Branded generics Off-patent products sold under a company or product name Private pharmacies, physicians, clinics Compete on price, availability, perceived quality, and promotion
INN generics Products sold under the active ingredient’s international nonproprietary name Public sector, price-sensitive private patients Lowest price, tender-driven, dependent on quality confidence and availability

The private market is led by large pharmacy chains, independent pharmacies, distributors, private clinics, and direct institutional sales. The public market is supplied through MINSA, regional governments, EsSalud, armed forces, police health systems, and social programs.

Peru does not publish a single, unified public data series that consistently separates innovative brands, branded generics, and INN generics across all channels. Market estimates therefore vary according to whether they include hospital procurement, retail sales, or wholesale values. The commercial pattern is clearer than the precise market share: private retail favors branded products and pharmacy substitution, while public procurement favors generic and multisource medicines.

How large is Peru’s pharmaceutical market and where is the growth?

Peru is one of the larger pharmaceutical markets in the Andean region, but it remains smaller than Brazil, Mexico, and Argentina. Growth is concentrated in medicines with public-health relevance and in private products that address chronic disease, specialty care, and self-medication demand.

The strongest demand categories include:

  • Cardiovascular medicines
  • Diabetes and metabolic therapies
  • Oncology products
  • Anti-infectives
  • Respiratory medicines
  • Gastrointestinal therapies
  • Central nervous system products
  • Vaccines and biologics
  • Hospital injectables and critical-care medicines

Private retail demand is supported by urban concentration, chronic disease, expanding private healthcare, and pharmacy-chain penetration. Public-sector demand is driven by essential medicines, oncology, HIV, tuberculosis, vaccines, reproductive health, and hospital treatment.

The largest commercial risk is channel concentration. A supplier may obtain national registration but still lack access to major pharmacy chains or public tenders. Market entry therefore requires a channel strategy, not only a regulatory filing.

What is the regulatory framework for medicines in Peru?

Peru’s principal pharmaceutical statute is Law No. 29459, which regulates pharmaceutical products, medical devices, and sanitary products. Its implementing framework includes Supreme Decree No. 016-2011-SA and related technical standards administered by DIGEMID (Congreso de la República del Perú, 2009; Ministerio de Salud del Perú, 2011).

DIGEMID registration

A pharmaceutical product generally requires sanitary registration before commercialization. The application typically includes:

  • Active ingredient and finished-product information
  • Manufacturing and quality documentation
  • Stability data
  • Labeling and package inserts in Spanish
  • Good Manufacturing Practice evidence
  • Pharmaceutical form and specifications
  • Manufacturing and testing-site details
  • Bioequivalence or interchangeability evidence where required
  • Pharmacovigilance and risk information for applicable products

The regulatory pathway depends on whether the product is:

  1. A new chemical entity or innovative product
  2. A generic pharmaceutical product
  3. A biological or biosimilar product
  4. A high-risk or narrow-therapeutic-index medicine
  5. A product with a new route, dosage form, or combination

Peru uses different levels of evidence depending on product type and risk. The practical burden is highest for innovative drugs, biologics, complex injectables, modified-release products, and products subject to interchangeability requirements.

Registration timing

Statutory timelines differ by product category and administrative pathway. Actual time to approval can be longer because of observations, incomplete dossiers, translation issues, document legalization, manufacturing-site questions, and requests for additional evidence. Foreign applicants usually operate through a local representative or holder of the sanitary registration.

Registration maintenance creates a separate workload. Renewals, variations, manufacturing-site changes, artwork updates, safety changes, and labeling modifications require active lifecycle management.

What is Peru’s generic drug policy?

Peru’s policy favors access to generic medicines by INN, particularly in the public sector. Prescriptions are expected to identify the active ingredient, while a brand may be added where applicable. The legal and policy direction has been to increase generic availability, improve price transparency, and reduce dependence on higher-priced branded products.

Law No. 32033, enacted in 2024, strengthened measures intended to promote access to generic medicines and increase obligations affecting prescribing, dispensing, availability, and consumer information. Its commercial impact depends on implementing rules, inspection intensity, and the ability of pharmacies and manufacturers to maintain reliable stock (Congreso de la República del Perú, 2024).

Generic policy creates opportunities for:

  • Multisource medicines with high public-sector demand
  • Branded generics with strong quality positioning
  • Contract manufacturing
  • Local packaging and secondary manufacturing
  • Hospital injectables
  • Products with supply shortages
  • Bioequivalent versions of high-volume chronic medicines

The principal challenge is that legal preference for generics does not automatically produce substitution. Physicians may continue prescribing brands, patients may associate price with quality, and pharmacies may favor products with higher commercial margins. Bioequivalence recognition and consistent product availability are central to changing those incentives.

What are the requirements for generic substitution and interchangeability?

Generic substitution in Peru is not uniform across all medicines. Requirements depend on product risk, dosage form, therapeutic index, route of administration, and applicable DIGEMID standards.

Interchangeability policy has developed through Supreme Decree No. 024-2018-SA and related technical standards. The framework establishes conditions under which a multisource product can demonstrate equivalence to a reference product through in vitro studies, bioequivalence studies, or other accepted evidence, depending on the medicine (Ministerio de Salud del Perú, 2018).

Higher-risk categories generally require more demanding evidence. These may include:

  • Narrow-therapeutic-index drugs
  • Modified-release products
  • Complex dosage forms
  • Certain locally acting products
  • Products with difficult pharmacokinetic characteristics
  • Selected biological products

A generic manufacturer’s commercial advantage is strongest when it has both sanitary registration and recognized interchangeability status. Registration alone may not persuade physicians, hospitals, or procurement agencies to substitute the product.

What is the FDA regulatory status and Orange Book position for Peru?

Peru does not have a U.S.-style FDA or Orange Book system.

DIGEMID is the national medicines regulator. The United States Food and Drug Administration regulates products marketed in the United States, but FDA approval does not automatically authorize commercialization in Peru. FDA, EMA, or other reference-agency approvals can support the Peruvian dossier, particularly where DIGEMID accepts reliance or reference-country documentation, but the applicant must still satisfy Peruvian registration requirements.

Peru also does not operate an Orange Book patent-listing system that automatically links generic approval to originator patents. Patent rights and sanitary registration are separate legal systems.

The practical consequences are:

  • No automatic Peruvian patent certification equivalent to a U.S. Paragraph IV filing
  • No general statutory patent-linkage mechanism comparable to the Hatch-Waxman system
  • No official Orange Book listing for pharmaceutical patents
  • Patent disputes are generally handled through INDECOPI and the courts
  • Regulatory approval does not itself determine freedom to operate

What patents protect drugs in Peru and when does exclusivity expire?

Peru grants patents under the Andean Community intellectual-property regime, principally Decision 486. A pharmaceutical patent generally has a 20-year term from the filing date, subject to the applicable legal rules and payment of maintenance fees (Comunidad Andina, 2000).

Relevant protection may include:

  • Compound or composition-of-matter patents
  • Polymorph, salt, stereoisomer, and crystal-form patents
  • Formulation and controlled-release patents
  • Dosage and dosing-regimen patents
  • Combination patents
  • Manufacturing-process patents
  • Use patents where legally available
  • Device or delivery-system patents

Peru’s patent landscape is less commercially dense than the U.S. market because there is no Orange Book-style listing regime and because some follow-on patents face patentability and enforceability scrutiny. A product can lose its core compound patent while retaining commercial protection through formulation, device, process, or method-of-use claims.

Patent term and regulatory delay

Peru’s patent term is generally 20 years from filing. Patent-term extensions comparable to the U.S. patent-term extension system are not a standard feature of the Peruvian framework. Regulatory delay therefore does not necessarily produce a corresponding extension of market exclusivity.

Patent term calculations should account for:

  • Priority date
  • Peruvian national filing date
  • PCT national-phase filing
  • Continuation or divisional treatment where applicable
  • Maintenance-fee status
  • Andean Community rules
  • Patent-office prosecution history

What are the Paragraph IV and generic launch risks in Peru?

Peru has no direct Paragraph IV procedure. A generic applicant can seek registration without making a U.S.-style certification against every listed originator patent because Peru has no equivalent patent-listing database.

That does not eliminate patent risk. Generic launch exposure can arise through:

  • Patent infringement claims by the originator
  • Preliminary injunction requests
  • Customs actions involving allegedly infringing goods
  • Patent opposition or invalidity proceedings
  • Trade-secret or confidential-information disputes
  • Unfair-competition claims
  • Contractual restrictions involving distributors or licensees

A launch assessment should separate regulatory readiness from commercial freedom to operate. The core questions are whether a valid Peruvian patent covers the proposed product, whether the claims read on the product or process, whether the patent is in force, and whether the launch could trigger an injunction.

Generic launch scenarios

Scenario Regulatory position Patent position Commercial risk
Core compound patent expired Registration generally possible Lower risk, subject to secondary patents Price erosion and rapid competition
Core patent active, no clear secondary patent Registration may proceed Litigation risk remains Launch delay or injunction exposure
Formulation patent active Generic may need a different formulation Product-specific infringement risk Need design-around strategy
Method-of-use patent active Product may be marketed for nonprotected uses, subject to claims Labeling and promotion risk Off-label and inducement concerns
Process patent active Alternative manufacturing route may avoid infringement Supply-chain and API risk Need supplier diligence
No valid patent identified Regulatory filing and launch feasible Freedom-to-operate risk is lower Tender and distribution execution become decisive

What is the biosimilar regulatory opportunity in Peru?

Peru’s biologics market creates opportunities in insulin, oncology, immunology, vaccines, erythropoietins, growth factors, and other hospital products. Biosimilar entry is more complex than conventional generic entry because approval depends on analytical comparability, clinical evidence, immunogenicity assessment, manufacturing controls, and pharmacovigilance.

Key barriers include:

  • High development and manufacturing costs
  • Limited local capacity for advanced biologics production
  • Cold-chain requirements
  • Physician concerns about switching
  • Procurement specifications that favor reference products
  • Need for robust post-market surveillance
  • Regulatory expectations that can vary by product category

Biosimilars may obtain a registration pathway without receiving automatic interchangeability with the reference biologic. Substitution and switching should therefore be assessed separately from marketing authorization.

How does public procurement affect branded and generic medicines?

Public procurement is one of the most important access routes in Peru. CENARES manages centralized procurement for selected medicines and health products, while regional and institutional entities conduct additional purchases. EsSalud has its own demand and procurement structure.

Public tenders emphasize:

  • Unit price
  • Technical compliance
  • Supply capacity
  • Delivery performance
  • Product quality
  • Regulatory status
  • Financial and administrative eligibility
  • Prior performance and sanctions history

A low registration price does not guarantee tender success. Suppliers must maintain production capacity, import planning, local inventory, and documentation. Stock-outs can damage future tender eligibility and commercial reputation.

Generic manufacturers can compete effectively when they combine low cost with dependable supply. Branded manufacturers may retain positions through clinical confidence, specialist demand, or inclusion in complex treatment protocols, but they face direct price pressure in tenders.

What licensing and partnership models work in Peru?

Foreign companies commonly use one of four structures:

  1. Local marketing authorization holder
  2. Exclusive distributor
  3. Licensing and supply agreement with a Peruvian company
  4. Regional model covering Peru through an Andean or Latin American partner

The appropriate model depends on product complexity and channel. Specialty products often require a local team capable of hospital access, pharmacovigilance, reimbursement work, and tender participation. High-volume generics require distribution scale, inventory discipline, and competitive cost.

A licensing agreement should allocate:

  • Registration ownership
  • Regulatory expenses
  • Pharmacovigilance duties
  • Recall responsibility
  • Minimum purchase commitments
  • Tender participation
  • Pricing authority
  • Patent and freedom-to-operate responsibility
  • Manufacturing-site changes
  • Supply interruption remedies
  • Change-of-control rights

What litigation and settlement issues affect pharmaceutical companies?

Peru does not have the same volume of pharmaceutical patent litigation as the United States. Disputes nevertheless arise in patent validity, infringement, trademarks, sanitary registration, advertising, public procurement, and unfair competition.

Key institutions include:

  • INDECOPI for patents, trademarks, unfair competition, and administrative proceedings
  • DIGEMID for regulatory enforcement and product surveillance
  • Peruvian courts for judicial review, injunctions, and broader civil disputes
  • Public procurement bodies for tender challenges and supplier sanctions

Settlement agreements should be reviewed for competition-law, public-procurement, and patent-enforcement implications. A settlement that delays generic entry or restricts supply can create scrutiny if it affects competition or public access.

How strong is the patent estate for a medicine in Peru?

Patent strength should be assessed through a product-specific landscape, not by counting global patent families. The relevant measures are:

  • Number of granted Peruvian patents
  • Remaining patent term
  • Claim scope
  • Claim overlap
  • Validity risk
  • Patent ownership and assignments
  • Maintenance-fee status
  • Pending applications
  • Manufacturing-route coverage
  • Formulation and device coverage
  • Litigation history
  • Availability of noninfringing alternatives

A strong Peruvian estate usually combines a valid core patent with enforceable secondary patents and practical barriers such as complex manufacturing, restricted API supply, or specialized delivery technology. A weak estate may still delay entry if litigation costs, injunction risk, or procurement barriers make launch unattractive.

What are the main regulatory opportunities and challenges in Peru?

Opportunities

  • Expansion of INN generic use
  • Government focus on essential-medicine access
  • Centralized procurement of high-volume medicines
  • Biosimilar and specialty-drug adoption
  • Contract manufacturing and local packaging
  • Regulatory reliance and foreign reference approvals
  • Digital pharmacovigilance and supply-chain systems
  • Chronic-disease treatment growth
  • Market entry through private pharmacy chains

Challenges

  • Variable approval timelines
  • Regulatory observations and dossier rework
  • Complex interchangeability requirements
  • Weak separation between prescription and dispensing incentives
  • Pharmacy-chain concentration
  • Public-tender price compression
  • Product shortages and import dependency
  • Enforcement of quality and advertising rules
  • Limited predictability for biologics and complex products
  • Patent and regulatory systems operating independently
  • Geographic disparities in distribution

Key Takeaways

  • Peru has a dual pharmaceutical market: branded and pharmacy-led in private retail, generic and tender-led in the public sector.
  • DIGEMID controls sanitary registration, while INDECOPI handles patents and other industrial-property rights.
  • Peru has no Orange Book and no direct U.S.-style Paragraph IV pathway.
  • Pharmaceutical patents generally last 20 years from filing under the Andean Community framework.
  • Generic approval does not establish freedom to operate, and patent clearance must be performed separately.
  • Interchangeability evidence is increasingly important for generic uptake, particularly in higher-risk categories.
  • Biosimilars offer growth potential but face higher evidence, manufacturing, procurement, and physician-acceptance barriers.
  • Public procurement rewards price and supply reliability, while private retail rewards brand recognition, distribution, and pharmacy access.
  • The highest-value entry strategies combine DIGEMID registration, patent clearance, local distribution, tender planning, and pharmacovigilance execution.

FAQs About Peru’s Pharmaceutical Market

Does Peru require generic medicines to be prescribed by INN?

Peruvian policy supports prescribing by international nonproprietary name, with brand identification where applicable. Enforcement and dispensing behavior vary by institution and pharmacy channel.

Can a generic drug enter Peru before an originator patent expires?

Sanitary registration and patent rights are separate. A generic may pursue regulatory approval, but commercial launch can expose the applicant to patent infringement claims if a valid Peruvian patent covers the product or its manufacturing process.

Is there patent linkage between DIGEMID and INDECOPI?

Peru does not operate a general patent-linkage mechanism equivalent to the U.S. system. DIGEMID registration does not automatically certify that a product is free of patent infringement.

Are biosimilars automatically interchangeable with reference biologics in Peru?

No. Biosimilar approval and interchangeability are separate issues. The applicable evidence and substitution status depend on the product, regulatory standards, and institutional practice.

Which channel is more attractive for generic drug companies in Peru?

Public procurement offers volume but imposes price and supply pressure. Private retail can produce better margins, but access depends on pharmacy chains, distributors, physician prescribing, consumer confidence, and inventory coverage.

References

Comunidad Andina. (2000). Decision 486: Common regime on industrial property. https://www.comunidadandina.org

Congreso de la República del Perú. (2009). Ley No. 29459, Ley de los productos farmacéuticos, dispositivos médicos y productos sanitarios. https://www.gob.pe

Congreso de la República del Perú. (2024). Ley No. 32033, ley que promueve el acceso y uso de medicamentos genéricos en denominación común internacional. https://www.gob.pe

Ministerio de Salud del Perú. (2011). Decreto Supremo No. 016-2011-SA, Reglamento para el registro, control y vigilancia sanitaria de productos farmacéuticos, dispositivos médicos y productos sanitarios. https://www.gob.pe

Ministerio de Salud del Perú. (2018). Decreto Supremo No. 024-2018-SA, disposiciones sobre intercambiabilidad de medicamentos. https://www.gob.pe

Dirección General de Medicamentos, Insumos y Drogas. (n.d.). Registro sanitario, vigilancia sanitaria e intercambiabilidad de medicamentos. Ministerio de Salud del Perú. https://www.digemid.minsa.gob.pe

More… ↓

⤷  Start Trial

DrugPatentWatch cited by CNN, NEJM, Nature Journals, and more …

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.